BiotechTube

DBV712 250 mcg

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Peanut Allergy

Conditions

Peanut Allergy

Trial Timeline

Dec 6, 2018 → May 13, 2025

NCT ID
NCT03859700

About DBV712 250 mcg

DBV712 250 mcg is a phase 3 stage product being developed by DBV Technologies for Peanut Allergy. The current trial status is completed. This product is registered under clinical trial identifier NCT03859700. Target conditions include Peanut Allergy.

What happened to similar drugs?

0 of 7 similar drugs in Peanut Allergy were approved

Approved (0) Terminated (1) Active (6)
❌ligelizumab + PlaceboNovartisPhase 3
🔄Omalizumab + Placebo for Omalizumab + Multi-Allergen Oral Immunotherapy + Placebo for Multi-Allergen Oral ImmunotherapyNovartisPhase 3
🔄Viaskin Peanut 250 mcg + PlaceboDBV TechnologiesPhase 3
🔄DBV712 + DBV712DBV TechnologiesPhase 3
🔄Part A Viaskin Peanut 250 mcg + Part A Viaskin Peanut 100 mcg + Part A Placebo + Part B Viaskin Peanut 250 mcg + Part B PlaceboDBV TechnologiesPhase 3
🔄Viaskin Peanut 250mcg + PlaceboDBV TechnologiesPhase 3
🔄Viaskin Peanut 250µgDBV TechnologiesPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03859700Phase 3Completed

Competing Products

20 competing products in Peanut Allergy

See all competitors
ProductCompanyStageHype Score
ASP0892 Intradermal + ASP0892 Intramuscular + Placebo Intradermal + Placebo IntramuscularAstellas PharmaPhase 1
29
ASP0892 + PlaceboAstellas PharmaPhase 1
29
ligelizumab + PlaceboNovartisPhase 3
32
remibrutinib + placeboNovartisPhase 2
35
QGE031 + PlaceboNovartisPhase 2
27
Omalizumab + Placebo for Omalizumab + Multi-Allergen Oral Immunotherapy + Placebo for Multi-Allergen Oral ImmunotherapyNovartisPhase 3
40
Dupilumab + Placebo matching dupilumab + AR101SanofiPhase 2
35
DupilumabSanofiPhase 2
35
Etokimab + PlaceboAnaptysBioPhase 2
29
DBV712 IHRPDBV TechnologiesPhase 1
23
Epicutaneous Immunotherapy + placebo of peanutDBV TechnologiesPhase 2
29
Viaskin Peanut 250 mcg + PlaceboDBV TechnologiesPhase 3
34
Viaskin PeanutDBV TechnologiesPre-clinical
20
Viaskin Peanut 50 mcg + Viaskin Peanut 100 mcg + Viaskin Peanut 250 mcg + Viaskin PlaceboDBV TechnologiesPhase 2
29
Whole peanut extract + Placebo formulationDBV TechnologiesPhase 1
23
Viaskin Peanut 250 mcgDBV TechnologiesPhase 2
29
DBV712 + DBV712DBV TechnologiesPhase 3
38
Part A Viaskin Peanut 250 mcg + Part A Viaskin Peanut 100 mcg + Part A Placebo + Part B Viaskin Peanut 250 mcg + Part B PlaceboDBV TechnologiesPhase 3
34
Viaskin Peanut 250mcg + PlaceboDBV TechnologiesPhase 3
34
Viaskin Peanut 250µgDBV TechnologiesPhase 3
30